Id3 induces an Elk-1–caspase-8-dependent apoptotic pathway in squamous carcinoma cells
Creators
- 1. Department of Biochemistry and Molecular and Cellular Biology, Georgetown University, Washington, District of Columbia, 20057 (United States)
- 2. Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, 402, Taiwan (China)
- 3. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, 20057 (United States)
Description
Inhibitor of differentiation/DNA-binding (Id) proteins are helix–loop–helix (HLH) transcription factors. The Id protein family (Id1–Id4) mediates tissue homeostasis by regulating cellular processes including differentiation, proliferation, and apoptosis. Ids typically function as dominant negative HLH proteins, which bind other HLH proteins and sequester them away from DNA promoter regions. Previously, we have found that Id3 induced apoptosis in immortalized human keratinocytes upon UVB exposure, consistent with its role as a tumor suppressor. To investigate the role of Id3 in malignant squamous cell carcinoma (SCC) cells (A431), a tetracycline-regulated inducible system was used to induce Id3 in cell culture and mouse xenograft models. We found that upon Id3 induction, there was a decrease in cell number under low serum conditions, as well as in soft agar. Microarray, RT-PCR, immunoblot, siRNA, and inhibitor studies revealed that Id3 induced expression of Elk-1, an E-twenty-six (ETS)-domain transcription factor, inducing procaspase-8 expression and activation. Id3 deletion mutants revealed that 80 C-terminal amino acids, including the HLH, are important for Id3-induced apoptosis. In a mouse xenograft model, Id3 induction decreased tumor size by 30%. Using immunofluorescent analysis, we determined that the tumor size decrease was also mediated through apoptosis. Furthermore, we show that Id3 synergizes with 5-FU and cisplatin therapies for nonmelanoma skin cancer cells. Our studies have shown a molecular mechanism by which Id3 induces apoptosis in SCC, and this information can potentially be used to develop new treatments for SCC patients
Availability note (English)
Available from http://dx.doi.org/10.1002/cam4.427; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472214Additional details
Identifiers
Publishing Information
- Journal Title
- Cancer medicine
- Journal Volume
- 4
- Journal Issue
- 6
- Journal Page Range
- p. 914-924
- ISSN
- 2045-7634
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 46093465
- Subject category
- S60: APPLIED LIFE SCIENCES; S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- AGAR; AMINO ACIDS; APOPTOSIS; CARCINOMAS; CELL CULTURES; DNA; HOMEOSTASIS; MICE; MUTANTS; PATIENTS; POLYMERASE CHAIN REACTION; PROLIFERATION; THERAPY; TRANSCRIPTION FACTORS
- Descriptors DEC
- ANIMALS; CARBOHYDRATES; CARBOXYLIC ACIDS; COLLOIDS; DISEASES; DISPERSIONS; GENE AMPLIFICATION; MAMMALS; MEDICINE; NEOPLASMS; NUCLEIC ACIDS; ORGANIC ACIDS; ORGANIC COMPOUNDS; POLYSACCHARIDES; PROTEINS; RODENTS; SACCHARIDES; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
- Notes
- PMCID: PMC4472214; PMID: 25693514; OAI: oai:pubmedcentral.nih.gov:4472214